cinacalcet sandoz 90 mg tabletki powlekane
sandoz gmbh - cinacalcetii hydrochloridum - tabletki powlekane - 90 mg
escitalopram aurovitas 10 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - escitaloprami oxalas - tabletki powlekane - 10 mg
escitalopram aurovitas 15 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - escitaloprami oxalas - tabletki powlekane - 15 mg
escitalopram aurovitas 20 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - escitalopramum - tabletki powlekane - 20 mg
rivaroxaban aurovitas 10 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - rivaroxabanum - tabletki powlekane - 10 mg
rivaroxaban aurovitas 15 mg/20 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - rivaroxabanum - tabletki powlekane - 15 mg/20 mg
imatinib accord
accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. za wyjątkiem zdiagnozowanych fazie przewlekłej cml, nie ma kontrolowanych badań, które wykazują efekt kliniczny lub zwiększa przeżywalność przy tych chorobach. .
calcium + cholecalciferol béres 600 mg + 800 j.m. tabletki powlekane
beres pharmaceuticals ltd. - calcium + cholecalciferolum, pulvis - tabletki powlekane - 600 mg + 800 j.m.
desetax 0,5 mg/ml roztwór doustny
aristo pharma sp. z o.o. - desloratadinum - roztwór doustny - 0,5 mg/ml
moxifloxacin genoptim 400 mg tabletki powlekane
synoptis pharma sp. z o.o. - moxifloxacini hydrochloridum - tabletki powlekane - 400 mg